

E-POSTER PRESENTATION INSTRUCTIONS

The abstract review committee tries to accommodate submitters preferred presentation format. However, **PLEASE BE AWARE THAT THE ABSTRACT COMMITTEE RESERVES THE RIGHT TO SELECT THE FINAL PRESENTATION FORMAT FOR ALL SUBMITTED ABSTRACTS IN ORDER TO MEET THE NEEDS OF CONFERENCE PLANNING.**

E-Poster presentations will take place on the AMMI Canada – CACMID Conference platform beginning on Sunday, April 25th, 2021. Presentation will be available to view on the platform until Sunday, May 30, 2021. Conference delegates will have the ability to interact with poster presenters via a chat function within the platform. You will be required to monitor the chat on your poster a minimum of once a day for the duration of the live conference by logging into the Conference Platform as a delegate. Please include an email on your poster where delegates can reach you for questions following the live days.

E-posters have the option of presenting either as single page PDF poster with no narration or a narrated PowerPoint. **Important:** This does not apply to Competing Student Posters which must be presented as a single page poster with no narration. If you also have a Student Poster accepted please see the [2021 Student Poster Schedule & Presentation Instructions](#).

Examples:

- I. [E-poster Single Page PDF Poster-no narration](#)
- II. [E-poster Multiple Slide, narrated PowerPoint](#) (downloadable file)

Narrated e-poster presentations should be submitted as a PowerPoint using a 16:9 ratio.

1. Open **PowerPoint** on your PC or Mac.
2. From the top menu, (depending on the version of **PowerPoint** you have) select Design, then Page Setup OR File, then Page Setup, and change Slides sized for to: On-screen Show (**16:9**).
3. Click OK.

Pre-recording audio: [Instructions for adding audio to a Powerpoint presentation](#)

If you have any trouble converting your presentation to 16:9 or adding audio please contact meetings@ammi.ca for assistance.

Presenters are required to submit their presentations via Drop Box no later than **March 31st, 2021**. Please upload your presentation using your Session Code and Presentation Title as the file name (Ex. *P01- Prevalence and clinical correlation of indeterminate Clostridium difficile tests utilizing a 2-step algorithm*) If changes need to be made to a presentation a new file must be uploaded to the Dropbox link, please add Version 2,3,4 and so on to the end of your title to indicate it is replacing an already submitted presentation. Changes can be made to your presentation until **March 31st, 2021**. You can [submit your presentation here](#).

IMPORTANT

- All presenting authors **MUST** be registered for the annual conference no later than **Wednesday, March 31st, 2021**. If registration is not complete by this date, the abstract will be REMOVED and will NOT be published. [Click Here to Register](#).



- All presentations must be uploaded to the [Drop Box Link](#) by **March 31st, 2021**.
- Should you need assistance or clarification please contact meetings@ammi.ca or call 1-866-467-1215 ext 103

2021 E-poster Presentation Schedule			
Session Code	Abstract Title	Presenter	Abstract ID
P01	Investigating the Efficacy of Insecticide-treated Window Screens and Eaves against Anopheles Mosquitoes	Beverly Anaele	10
P02	Outcomes of a Risk-Based Decision-Making Process for Reducing the Risk of Hepatitis E Virus Transfusion Transmission via the Canadian Blood Supply	Steven Drews	14
P03	Evaluation of the NG-Test Carba 5 Multiplex Immunochromatographic Assay and Cepheid Xpert Carba-R Assay for the Detection of Carbapenemase Genes in Gram Negative Organisms	Ghada Al-Rawahi	24
P04	SARS-CoV-2 transmission through cells, tissues and organs transplantation	Amaury Gausson	25
P05	One Health genomic study of extended spectrum beta-lactamases (ESBL)-producing Salmonella enterica in Canada, 2012-2016	Amrita Bharat	26
P06	Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosis	David Claveau	34
P07	A virtual care model utilizing patient directed oximetry monitoring for outpatients with COVID-19: A quality improvement study	Megan Devlin	35
P08	Case report: Actinotignum schaalii identified in a neck abscess of a pediatric patient	Ruwandi Kariyawasam	38
P09	Synergistic activity of combinations of colistin with other antibiotics against multidrug- and extensively drugresistant clinical isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa	Tatiana Petrovskaya	42
P10	The vancomycin minimum inhibitory concentration of Staphylococcus species isolated from children's blood culture	Eugene Yeung	43
P11	Microbiological efficiency of the combinations of two carbapenems against Klebsiella pneumoniae carbapenemase-producing strains	Elena Timoskova	45
P12	Waning anti-SARS-CoV2-2 plaque reduction neutralization test titers in repeat Canadian convalescent plasma donors: April-December 2020.	Steven Drews	48



April 28 - May 01 / 28 avril - 1^{er} mai

ANNUAL CONFERENCE

CONFÉRENCE ANNUELLE

AMMI Canada - CACMID



Session Code	Abstract Title	Presenter	Abstract ID
P13	Impact of the COVID-19 pandemic on the incidence and serotype distribution of invasive pneumococcal disease in south-central Ontario	Allison McGeer	51
P14	Impact of an antimicrobial stewardship initiative to reduce asymptomatic bacteriuria in a tertiary hospital	Maggie Wong	53
P15	Development of quality indicators to evaluate appropriate empiric antimicrobial use in pediatric patients	Emily Black	59
P16	Penicillin Susceptibility in Staphylococcus aureus – An Opportunity for Antimicrobial Stewardship?	Philippe Lagacé-Wiens	63
P17	Nosocomial SARS-CoV-2 infection in healthcare workers (HCWs): descriptive analysis of a large acute care hospital COVID-19 outbreak on cardiac units.	Devika Dixit	64
P18	Verification of the Vitek® 2 N391 Gram-Negative AST Card - Results are Method-Dependent	Philippe Lagacé-Wiens	65
P19	Evaluation of the Solana® Influenza A and B Nucleic Acid Amplification Assay	Philippe Lagacé-Wiens	66
P20	Stepwise implementation of an antimicrobial stewardship prospective audit and feedback intervention at a large academic centre in Canada	Justin Chen	68
P21	SARS-CoV2 outbreak amongst physicians at a Canadian curling bonspiel: a descriptive observational study	Bonnie Meatherall	71
P22	Verification of 2019 CLSI M100 Revised Ciprofloxacin Breakpoints for Pseudomonas aeruginosa using the Vitek® 2 N391 Gram-Negative AST Card	Philippe Lagacé-Wiens	72
P23	Congenital SARS-CoV-2 infection in a pre-term neonate with viable virus from the placenta	Joseph Vayalumkal	75
P24	Comparative analysis of capillary versus venous blood for serologic detection of SARS-CoV-2 antibodies by rPOC lateral flow tests	Tamara Pidduck	77
P25	Cefiderocol therapy in a Canadian urban academic centre: A new option to treat carbapenem-resistant gram-negative infections	Christine Ondro	78



Session Code	Abstract Title	Presenter	Abstract ID
P26	Survey results from a pilot antimicrobial stewardship prospective audit and feedback in general surgery	April Chan	79
P27	Associated antibiotic use for community infections in British Columbia: a review of prescribing from 2000 – 2018.	Ariana Saatchi	82
P28	The impact of a reported beta-lactam allergy on cefazolin administration in surgical prophylaxis: cefazolin is still best, but is it given?	Holly Hoang	83
P29	A review of surgical antibiotic prophylaxis practice in adult urology procedures: opportunities for antimicrobial stewardship collaboration	Justin Chen	84
P30	Real-life experience with ceftobiprole in Canada: results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) Registry	George Zhanel	90
P31	An examination of selection, timing and duration of surgical prophylaxis for vascular procedures at a major Canadian vascular surgery centre	Holly Hoang	91
P32	An audit of surgical antibiotic prophylaxis in orthopedic surgery with particular focus on duration of prophylaxis	Susan Fryters	93
P33	An assessment of surgical antibiotic prophylaxis practices at a Canadian tertiary pediatric centre	Alena Tse-Chang	94
P34	Comparison of contact precautions with routine practices for the prevention of vancomycin-resistant Enterococci(VRE) infections in hospitals: The secret is in the routine	Heather Glassman	95
P35	What's in a number? The value of titres as routine proof of immune protection	Natalie Marshall	103
P36	A case of multisystem inflammatory syndrome in adults (MIS-A): a rare manifestation of COVID-19	Teagan King	104
P37	Absence of Transmission of NDM and OXA-48-like Carbapenemase Genes in a Long-term Care Facility	Carl Boodman	112
P38	Sensitivity of Cobas® 68/8800 SARS-CoV-2 test using gargle specimens with two different processing methods	Patrick Benoit	117
P39	Evaluation of the Q Score for Assessing Wound Swab Quality in a Tertiary Care Centre	Shawn Clark	118



Session Code	Abstract Title	Presenter	Abstract ID
P40	Susceptibility patterns for Enterococcus spp. clinical isolates collected over a 14-year period	Victoria Bugaj	122
P41	Maternal and fetal infection of non-typhoidal Salmonella during pregnancy	Xena Li	123
P42	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry	George Zhanel	129
P43	Risks factors for severe outcomes in patients hospitalized with COVID-19 in a network of Canadian acute-care hospitals	Robyn Mitchell	141
P44	Reliability of E-gene Cycle Threshold (Ct) Values in Interpreting Duration of COVID-19 Infection	William Stokes	143
P45	Susceptibility of Pseudomonas Aeruginosa to Empiric Therapy and alternative β -lactam Antimicrobials in Intensive Care Unit Patients with Respiratory Tract Infections in Canadian Centers: SMART Surveillance (2016-2019)	Radwan El Ali	144
P46	Nasopharyngeal Expression of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in Children Compared to Adults Within Family Clusters Exposed to COVID-19	Mohammad Hasan	145
P47	The association of frailty and outcomes among hospitalized COVID19 patients in Toronto	Christopher Kandel	150
P48	Real-life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry	George Zhanel	153
P49	Antimicrobial resistance trends of Staphylococcus aureus isolates collected from patients over 14 years	Dylan Bedi	156
P50	Limitations of statistical methods used to determine the vancomycin therapeutic range: A data simulation experiment.	Bruce Dalton	157
P51	Prescribing pattern of restricted antimicrobials at a quaternary care academic hospital	Justin Chen	158
P52	A Quality Audit of Surgical Antibiotic Prophylaxis Timing, Redosing, and Post-Operative Dosing Practices in 5 Hospital Sites: The Devil is in the Details	Lynora Saxinger	159
P53	Targeted plasma metabolomics method for the diagnosis of acute SARS-CoV-2	Catherine Hogan	160



Session Code	Abstract Title	Presenter	Abstract ID
P54	Lineage distributions of SARS-CoV-2 during the second wave in British Columbia	Kimia Kamelian	162
P55	Assessment of fungal ITS PCR performance in formalin-fixed paraffin-embedded tissues	Shawn Clark	163
P56	Comparative genomics analysis of an IncR plasmid encoding blaNDM-1 from Enterobacter hormaechei involved in outbreak in Quebec.	Florence Doualla-Bell	164
P57	Y. regensburgei Infection in an Immunocompetent Host	Fatimah AlMutawa	165
P58	Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies	Erin Carruthers	168
P59	Necrotic myositis in an immunocompetent patient with persistent Bacillus cereus bacteremia and acute liver failure: A Case Report	Anna Cvetkovic	170
P60	How has antimicrobial use changed during the COVID-19 pandemic? A look at community antimicrobial use in Canada	Braden Knight	171
P61	Isolating Candida auris at Humber River Hospital: A Comparative Evaluation of Media to Develop a Screening Protocol for an Emerging Pathogen	Chantal Morris	173
P62	Comparison of the Sensititre CAN1MSTF panel and the BD Phoenix NMIC-450 panel for susceptibility testing of multi-drug resistant gram negative organisms	Lisa Li	174
P63	Community antibiotic use at the population level during the SARS-CoV2 pandemic in British Columbia, Canada	Abdullah Mamun	175
P64	Prospective audit and feedback (PAF) in level II neonatal intensive care units (NICU) – Is it worth it?	Khaled Alsager	178
P65	Validation of the triplex real-time RT-PCR assay for detection of Chikungunya, Dengue, and Zika viruses	Min-Kuang Lee	179
P66	Viral co-circulation during the COVID-19 pandemic: Broad respiratory testing to inform diagnostic stewardship	Natalie Marshall	180
P67	The Impact of ID Consultation in Patients with Enterococcus species Bloodstream Infection	Brittany Kula	184



Session Code	Abstract Title	Presenter	Abstract ID
P68	Comparison of the BD Phoenix CPO Detect Test and the NG-Test® CARBA-5 lateral flow assay for the detection of carbapenemase-producing organisms	Lisa Li	185
P69	Performance of three different screening media for the detection of carbapenemase-producing organisms	Lisa Li	186
P70	Comparison of two commercial broth microdilution methods for testing susceptibility to colistin in multi-drug resistant gram negative organisms	Lisa Li	187
P71	An audit of surgical antibiotic prophylaxis in obstetrical/gynecological surgery	Holly Hoang	190
P72	Using Propidium Monoazide in Real-Time Quantitative PCR to Distinguish Viable Verses Non-Viable Enteric Viruses in Water Samples	Melissa Glier	193
P73	Validation of gargle samples on the point-of-care cobas Liat for the detection of SARS-CoV-2	Judith Fafard	194
P74	Cohort study of children hospitalized with COVID-19 infection	Joan Robinson	195
P75	Evaluation of the Allplex™ 2019-nCoV assay for the detection of SARS-CoV-2 in a variety of clinical matrices	Shawn Clark	196
P76	Analysis of the performance of water gargle samples for SARS-CoV-2 detection by RT-PCR in a pediatric population	Emilie Vallières	198
P77	Persistent Pandoraea sputorum bacteremia in a patient with extensive burns: a case report	Victoria Weaver	200
P78	Validation of the EuroImmuno Anti-SARS-CoV-2 ELISA Assay for Detection of IgG and IgA Antibodies in Human Breast Milk	Shaista Anwer	201
P79	Ct as an Indicator of SARS-CoV-2 WGS success	Kimberley Macdonald	203
P80	A Novel Laboratory Informatics System for COVID-19 Outbreak Response and Whole Genome Sequencing of Pathogens for Public Health in British Columbia	Chris Fjell	204
P81	Expediting QC for COVID WGS analysis via Dashboards	Kimberley Macdonald	205
P82	The Frequency of Carbapenemase-producing Enterobacterales During COVID-19	Shaista Anwer	206
P83	Realization of theoretical savings following implementation of bioMérieux's VITEK® MS for rapid microbial identification in patients with blood stream infections	Georgia Carr	207



April 28 - May 01 / 28 avril - 1^{er} mai

ANNUAL CONFERENCE

CONFÉRENCE ANNUELLE

AMMI Canada - CACMID

P84	Human Herpes Virus-6 Surveillance in Hematopoietic Stem Cell Transplantation Patients	Sara Abolghasemi	211
P85	OPAT Quality Indicators at a Tertiary Care Centre Reveal Vast Room for Improvement.	Evan Wilson	212
P86	Emergency Department Visits and Readmission Rates of Patients Discharged on OPAT: A Retrospective Observational Study to Identify Predictors	Evan Wilson	213